CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today announced that the Company will present new data on three of its clinical and preclinical programs at the American Association for Cancer Research (AACR) Annual Meeting taking place April 1-5 in Washington, D.C.
The new data will be highlighted in five presentations:
- Three on SY-1425, an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist that is currently in a Phase 2 clinical trial in defined subsets of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients with a RARA biomarker;
- One on SY-1365, a first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor that is on track to begin a Phase 1 trial in the first half of this year in transcriptionally driven solid tumors; and
- One on its cyclin-dependent kinase 12/13 (CDK12/13) inhibitor program.
“The presentations at AACR showcase both the productivity of Syros’ gene control platform and the potential of our first-in-class programs to provide a meaningful benefit for patients with a range of aggressive cancers both as single agents and in combination with other targeted therapies,” said Nancy Simonian, M.D., Chief Executive Officer of Syros. “Our platform is the first focused solely on the regulatory genome to systematically identify and target disease-causing alterations in gene expression with the aim of treating diseases that have eluded other genomic-based approaches. In just three years since our inception, this pioneering approach has led to a robust and growing pipeline, with our lead program in a Phase 2 clinical trial, our second program poised to start clinical development in the first half of this year and multiple other programs in preclinical development. We are excited to be presenting data from multiple programs across all stages of our pipeline.”
Details on the presentations are as follow:
Date & Time: Monday, April 3, from 8 a.m. - 12 p.m. ET
Presentation
Title: AML patient clustering by super-enhancers reveals an RARA
associated transcription factor signaling partner
Session Category:
Molecular and Cellular Biology / Genetics
Session Title: Targeting
Aberrant Transcription in Cancer
Presenter: Michael R. McKeown,
Ph.D., Senior Scientist, Translational Biology, Syros
Abstract
Number: 1511
Location: Walter E. Washington Convention Center,
Halls A-C, Poster Section 20
Date & Time: Monday, April 3, from 8 a.m. - 12 p.m. ET
Presentation
Title: SY-1365, a potent and selective CDK7 inhibitor, exhibits
promising anti-tumor activity in multiple preclinical models of
aggressive solid tumors
Session Category: Experimental and
Molecular Therapeutics
Session Title: New Targets 1
Presenter:
Christian Fritz, Ph.D., Vice President, Biology, Syros
Abstract
Number: 1151
Location: Walter E. Washington Convention Center,
Halls A-C, Poster Section 4
Date & Time: Monday, April 3, from 8 a.m. - 12 p.m. ET
Presentation
Title: Targeting the transcriptional kinases CDK12 and CDK13 in breast
and ovarian cancer
Session Category: Experimental and Molecular
Therapeutics
Session Title: New Targets 1
Presenter: Michael
Bradley, Ph.D., Principal Scientist, Biochemistry & Biophysics, Syros
Abstract
Number: 1143
Location: Walter E. Washington Convention Center,
Halls A-C, Poster Section 4
Date & Time: Monday, April 3, from 1 - 5 p.m. ET
Presentation
Title: SY-1425, a selective RARα agonist, induces high levels of CD38
expression in RARA-high AML tumors creating a susceptibility to
anti-CD38 therapeutic antibody treatment
Session Category:
Immunology
Session Title: Immune Response to Hematopoietic Tumors:
New Development in Tumor Immunology
Presenter: Kathryn Austgen,
Ph.D., Senior Scientist, Immuno-Oncology, Syros
Abstract Number:
2644
Location: Walter E. Washington Convention Center, Halls A-C,
Poster Section 26
Date & Time: Tuesday, April 4, from 8 a.m. – 12 p.m. ET
Presentation
Title: SY-1425 (tamibarotene), a selective RARα agonist, shows
synergistic anti-tumor activity with hypomethylating agents in a
biomarker selected subset of AML
Session Category: Experimental and
Molecular Therapeutics
Session Title: Differentiation Therapy
Presenter:
Michael R. McKeown, Ph.D., Senior Scientist, Translational Biology, Syros
Abstract
Number: 3085
Location: Walter E. Washington Convention Center,
Halls A-C, Poster Section 3
About Syros Pharmaceuticals
Syros Pharmaceuticals is
pioneering the understanding of the non-coding region of the genome to
advance a new wave of medicines that control expression of
disease-driving genes. Syros has built a proprietary platform that is
designed to systematically and efficiently analyze this unexploited
region of DNA in human disease tissue to identify and drug novel targets
linked to genomically defined patient populations. Because gene
expression is fundamental to the function of all cells, Syros’ gene
control platform has broad potential to create medicines that achieve
profound and durable benefit across a range of diseases. Syros is
currently focused on cancer and immune-mediated diseases and is
advancing a growing pipeline of gene control medicines. Syros’ lead drug
candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical
trial for genomically defined subsets of patients with acute myeloid
leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7
inhibitor with potential in a range of solid tumors and blood cancers.
Led by a team with deep experience in drug discovery, development and
commercialization, Syros is located in Cambridge, Mass.
Cautionary Note Regarding Forward-Looking Statements
This
press release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995, including without
limitation statements regarding the clinical progress of and potential
benefits from treatment with SY-1425, the initiation of clinical
development of SY-1365, the ability to advance preclinical programs, and
the benefits of Syros’ gene control platform. The words ‘‘anticipate,’’
‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’
‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’
‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended
to identify forward-looking statements, although not all forward-looking
statements contain these identifying words. Actual results or events
could differ materially from the plans, intentions and expectations
disclosed in these forward-looking statements as a result of various
important factors, including: Syros’ ability to: advance the development
of its programs, including SY-1425 and SY-1365, under the timelines it
projects ; obtain and maintain patent protection for its drug candidates
and the freedom to operate under third party intellectual property;
demonstrate in any current and future clinical trials the requisite
safety, efficacy and combinability of its drug candidates; replicate
scientific and non-clinical data in clinical trials; successfully
develop a companion diagnostic test to identify patients with biomarkers
associated with the RARA super-enhancer; obtain and maintain necessary
regulatory approvals; identify, enter into and maintain collaboration
agreements with third parties; manage competition; manage expenses;
raise the substantial additional capital needed to achieve its business
objectives; attract and retain qualified personnel; and successfully
execute on its business strategies; risks described under the caption
“Risk Factors” in the company’s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2016, which is on file with the Securities
and Exchange Commission; and risks described in other filings that the
company makes with the Securities and Exchange Commission in the future.
Any forward-looking statements contained in this press release speak
only as of the date hereof, and Syros expressly disclaims any obligation
to update any forward-looking statements, whether because of new
information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170301006330/en/
